Sepsis Diagnostics Market - By Product (Instruments, Assay Kits & Reagents, Blood Culture Media, Software), By Technology (Microbiology, Molecular Diagnostics, Immunoassays, Flow Cytometry), By Method Type, By Pathogen Type, By End-use – Global Forecast to 2032

Sepsis Diagnostics Market Size

Sepsis Diagnostics Market size was valued at over USD 620 million in 2022 and is projected to reach more than USD 1.2 billion by 2032. Rising awareness regarding infectious diseases and its diagnosis will drive the market expansion.
 

Sepsis diagnostics refer to the processes and methods used to identify and diagnose sepsis, a potentially life-threatening condition caused by a severe infection. Sepsis occurs when the body's response to an infection triggers widespread inflammation, leading to organ dysfunction and failure. Rapid and accurate diagnosis of sepsis is crucial for timely and appropriate medical intervention, as the condition can progress rapidly and become fatal. The increasing demand for diagnostics sepsis devices is anticipated to foster the market share.
 

Moreover, the rising incidence of hospital-acquired infections, growing number of geriatric population base, immunocompromised patients, and chronic illness patients, is further augmenting the market value. For instance, according to the World Health Organization (WHO), sepsis affects an estimated 49 million individuals and causes 11 million deaths globally, every year. Further, around half (49%) of patients with sepsis in intensive care units acquire infection in the hospital, annually.
 

COVID-19 Impact

The COVID-19 pandemic had a significant impact on the sepsis diagnostics market. The COVID-19 pandemic increased healthcare practitioners' understanding of the risk of sepsis in infected patients. As a result, there has been a greater focus on sepsis detection and management. The global expansion of COVID-19 and the appearance of sepsis cases among COVID-19 patients increased demand for prompt diagnosis, leading to faster adoption of sepsis detection devices, reagents, and test kits. Therefore, the COVID-19 had a positive impact on the market growth.
 

Sepsis Diagnostics Market Trends

Advances in sepsis diagnosis have been a major driving force in the sepsis diagnostics industry. Furthermore, an increase in the prevalence of sepsis and growth in the worldwide geriatric population base is attributed to an increase in the demand for sepsis diagnostics. Additionally, an increase in government funding for sepsis-related research efforts, as well as an increase in the incidence of infectious ailments, are predicted to accelerate market trends.
 

Sepsis Diagnostics Market Analysis

Based on product, the sepsis diagnostics market is bifurcated into instruments, assay kits & reagents, blood culture media, and software. Blood culture media is anticipated to account for a significant revenue approximately 224 million in 2022. Blood culture media are generally less expensive compared to other types of sepsis diagnostics. Moreover, they are more convenient due to their high availability in the market. Additionally, the growing utilization of blood culture media by hospitals & pathology labs contributes to accelerating the market growth.

Based on technology, the sepsis diagnostics market is bifurcated into microbiology, molecular diagnostics, immunoassays, and flow cytometry. Microbiology segment held the highest CAGR at 7.8% during the forecast period. Due to the low cost of microbiology technology and accurate detection & identification of microorganisms for sepsis, microbiology has dominated the market. Moreover, extensive use of blood culture methods for the diagnosis of sepsis will considerably increase the adoption of microbiology.

The sepsis diagnostics market is bifurcated based on the method type including conventional diagnostics and automated diagnostics. Conventional diagnostics held a significant revenue around 339 million and is estimated to grow approximately 697 million by 2032. Conventional diagnostics ensures early detection and prompt treatment of sepsis. Moreover, it requires healthcare professionals’ expertise to evaluate and interpret the laboratory & imaging data which results in early and accurate detection. Further, the cost-effectiveness of conventional diagnostics as compared to automated diagnostics will spur the business landscape.

Based on pathogen type, the sepsis diagnostics market is bifurcated into bacterial sepsis, fungal sepsis, and others. Bacterial sepsis is leading the market due to an increase in bacterial sepsis patients and a rise in surgical operations. Furthermore, the increased occurrence of hospital-acquired infections in individuals that are already suffering from ill ailments leads to bacterial sepsis.

Based on end-use, the sepsis diagnostics market is divided into hospitals, diagnostic centres, clinics, and others. Hospitals held a significant revenue around 300 million and is estimated to grow approximately 618 million by 2032. The high frequency of sepsis, along with a large number of fatalities caused by disease and an increasing number of patients owing to improved awareness, will result in hospitals dominating the sepsis diagnostics industry. Furthermore, improved research and diagnosis in hospital laboratories, as well as increased disposable income in developed nations, will significantly contribute to the use of sepsis diagnostics in hospitals, resulting in segment expansion.

The presence of highly developed healthcare systems and the implementation of innovative sepsis diagnostic technologies has enhanced the need for sepsis diagnostics in North America. Furthermore, rising instances of healthcare-associated infections as a result of an increasing number of surgical operations and technological improvements, notably in North America, will drive the potential for market outlook in the coming years.
 

Sepsis Diagnostics Market Share

Some of the notable key industry players operating in the sepsis diagnostics market include

• Abbott Laboratories
• BioMerieux SA
• Thermo Fisher Scientific Inc.
• Becton, Dickinson, and Company
• Bruker Corporation
• Beckman Coulter, Inc.
• T2 Biosystems, Inc.
• Nanosphere, Inc.
• Hoffmann-LA Roche Ltd.
• Danaher Corporation

These market participants are implementing various growth strategies such as collaborations, partnerships, acquisitions & mergers, and new product development and launches to strengthen product offerings as well as gain a competitive edge over others.
 

Sepsis Diagnostics Industry News:

• In May 2020, in the U.S., Beckman Coulter unveiled the DxH 690T haematology analyzer with early sepsis signs. Such advanced product launches are anticipated to bolster market growth.
   

Sepsis diagnostics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product (USD Million)

• Blood culture media
• Instruments
• Assay kits & reagents
• Software      

By Technology (USD Million)

• Microbiology
• Molecular diagnostics
• Immunoassays
• Flow cytometry

By Method Type (USD Million)

• Conventional diagnostics
• Automated diagnostics

By Pathogen Type (USD Million)

• Bacterial sepsis
• Fungal sepsis
• Others

By End-use (USD Million)

• Hospitals
• Diagnostic centres
• Clinics
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Russia
  • Poland
  • Switzerland
  • Norway
  • Finland
  • Sweden
  • Denmark
  • The Netherlands
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Taiwan
  • Indonesia
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Israel